As a prominent player in the pharmaceuticals industry, Eli Lilly continues to demonstrate strong market performance. For detailed analysis including 13 additional ProTips and comprehensive ...

Bernstein SocGen Group reiterated an Outperform rating and $1,100.00 price target on Eli Lilly (NYSE: LLY) stock Monday, citing continued strong performance of its weight loss medication Zepbound ...

In 2024, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound generated $8 billion and $4.9 billion, respectively. So, this is approximately a $15 billion market ... loss is its impact on meaningful ...

Lilly announced the results on Wednesday, claiming that Zepbound outperforms Wegovy, which has been a leader in the weight loss market ... trial that examined the impact of both drugs on patients ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

The has already reduced its outlook for 2025 (discussed in the next section) owing to the impact ... treatments market faces a big challenge as chief rival Eli Lilly's (LLY) Zepbound is catching ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide ... chiefly that it was not a blinded analysis and participants knew which medication they ...

(Reuters) -Hims & Hers Health (HIMS) is betting that the cash-pay market for weight-loss drugs ... as well as branded Wegovy and Eli Lilly's (LLY) rival Zepbound. But analysts question whether ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...